subscribeSubscribe
Johnson & Johnson 1Q Results

Johnson & Johnson 1Q Results
CONTRACT PHARMA
20 May 2024
Share Share
ERLEADA® Combo Shows 100% Biochemical Control Post-Prostatectomy

ERLEADA® Combo Shows 100% Biochemical Control Post-Prostatectomy
PR NEWSWIRE
03 May 2024
Share Share
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105

Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105
GLOBENEWSWIRE
30 Jan 2024
Share Share
Erleada Approved as the Only Androgen Receptor Inhibitor in Canada

Erleada Approved as the Only Androgen Receptor Inhibitor in Canada
NEWSWIRE
10 Aug 2023
Share Share
Erleada, First Next-Generation Androgen Receptor Inhibitor Available in U.S.

Erleada, First Next-Generation Androgen Receptor Inhibitor Available in U.S.
PR NEWSWIRE
03 Apr 2023
Share Share
Hope as FDA approves injectable drug for resistant HIV

Hope as FDA approves injectable drug for resistant HIV
Amina Wako NATION
03 Jan 2023
Share Share
J&J takes Aurobindo to court over potential Erleada generic

J&J takes Aurobindo to court over potential Erleada generic
N. DeFeudis ENDPTS
01 Jun 2022
Share Share
FDA Confirms Para IV Patent Litigation for Apalutamide tablets.

FDA Confirms Para IV Patent Litigation for Apalutamide tablets.
FDA
06 Apr 2022
Share Share
New ERLEADA Analysis Demonstrates Rapid, Deep PSA Response in mCSPC

New ERLEADA Analysis Demonstrates Rapid, Deep PSA Response in mCSPC
PRESS RELEASE
14 Feb 2022
Share Share
J&J to divide into consumer health and pharmaceutical businesses

J&J to divide into consumer health and pharmaceutical businesses
PHARMACEUTICAL-TECHNOLOGY
15 Nov 2021
Share Share